Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NCX1000

Known as: NCX 1000, NCX-1000 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of… Expand
  • table 1
  • figure 2
  • table 2
  • figure 1
  • table 3
Is this relevant?
2007
2007
Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… Expand
Is this relevant?
2004
2004
1. NCX-1000, (3alpha, 5beta, 7beta)-3,7-dihydroxycholan-24oic acid[2-methoxy-4-[3-[4-(nitroxy)butoxy]-3-oxo-1-propenyl]phenyl… Expand
Is this relevant?
2004
2004
Recent advances in the knowledge of the pathophysiology of portal hypertension show that cirrhotic liver exhibits endothelial… Expand
Is this relevant?
Review
2004
Review
2004
Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… Expand
Is this relevant?
2003
2003
BACKGROUND/AIMS We studied whether acute administration of NCX-1000, a nitric oxide (NO)-releasing derivative of ursodeoxycholic… Expand
Is this relevant?
2003
2003
BACKGROUND/AIMS A decreased intra-hepatic nitric oxide (NO) production participates on the pathogenesis of portal hypertension in… Expand
Is this relevant?
2003
2003
To improve the reported synthetic route of NCX 1000 Using ferulic acid and 1,4 dibromobutane as the starting materials to prepare… Expand
Is this relevant?
2001
2001
Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a… Expand
Is this relevant?
2001
2001
Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?